265 related articles for article (PubMed ID: 36889160)
1. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
Chisamore N; Danayan K; Rodrigues NB; Di Vincenzo JD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; McIntyre RS; Rosenblat JD
J Psychopharmacol; 2023 Aug; 37(8):775-783. PubMed ID: 37194253
[TBL] [Abstract][Full Text] [Related]
6. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Gill H; Nasri F; Ling R; Teopiz KM; Ho RC; Subramaniapillai M; Kratiuk K; Mansur RB; Jones BDM; Lee Y; Rosenblat JD
J Affect Disord; 2021 Nov; 294():592-596. PubMed ID: 34332360
[TBL] [Abstract][Full Text] [Related]
7. Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Focus (Am Psychiatr Publ); 2023 Oct; 21(4):420-429. PubMed ID: 38694999
[TBL] [Abstract][Full Text] [Related]
8. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
[TBL] [Abstract][Full Text] [Related]
9. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Cha DS; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
J Psychiatr Res; 2021 Apr; 136():444-451. PubMed ID: 32948309
[TBL] [Abstract][Full Text] [Related]
10. Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.
Di Vincenzo JD; Lipsitz O; Rodrigues NB; Jones BDM; Gill H; Lee Y; Lui LMW; Teopiz KM; Ho R; Lin K; Nasri F; McIntyre RS; Rosenblat JD
Psychiatry Res; 2022 Jan; 307():114321. PubMed ID: 34890909
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
[TBL] [Abstract][Full Text] [Related]
12. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
[TBL] [Abstract][Full Text] [Related]
13. Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence.
Di Vincenzo JD; Lipsitz O; Rodrigues NB; Lee Y; Gill H; Kratiuk K; Subramaniapillai M; Mansur R; McIntyre RS; Rosenblat JD
J Psychiatr Res; 2021 Nov; 143():209-214. PubMed ID: 34507101
[TBL] [Abstract][Full Text] [Related]
14. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Gill H; Subramaniapillai M; Kratiuk K; Nasri F; Mansur RB; Rosenblat JD
CNS Spectr; 2022 Jun; 27(3):322-330. PubMed ID: 33267928
[TBL] [Abstract][Full Text] [Related]
15. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Subramaniapillai M; Kratiuk K; Majeed A; Nasri F; Gill H; Mansur RB; Rosenblat JD
Psychiatry Res; 2021 Jun; 300():113860. PubMed ID: 33836470
[TBL] [Abstract][Full Text] [Related]
16. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Lee Y; Gill H; Majeed A; Phan L; Nasri F; Ho R; Lin K; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
J Affect Disord; 2020 Nov; 276():570-575. PubMed ID: 32871688
[TBL] [Abstract][Full Text] [Related]
17. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
McIntyre RS; Rosenblat JD; Rodrigues NB; Lipsitz O; Chen-Li D; Lee JG; Nasri F; Subramaniapillai M; Kratiuk K; Wang A; Gill H; Mansur RB; Ho R; Lin K; Lee Y
Psychiatry Res; 2021 Aug; 302():113993. PubMed ID: 34034067
[TBL] [Abstract][Full Text] [Related]
18. Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Więdłocha M; Marcinowicz P; Komarnicki J; Tobiaszewska M; Dębowska W; Dębowska M; Szulc A
Front Psychiatry; 2024; 15():1398859. PubMed ID: 38742125
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation.
Rodrigues NB; Siegel A; Lipsitz O; Cha DS; Gill H; Nasri F; Simonson K; Shekotikhina M; Lee Y; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; McIntyre RS; Rosenblat JD
CNS Spectr; 2022 Jun; 27(3):315-321. PubMed ID: 33298225
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
